-
摘要:
信号淋巴细胞激活分子成员7（SLAMF7）不仅表达于多种肿瘤细胞表面，也表达于众多免疫细胞中，如自然杀伤细胞、CD4+T细胞、CD8+T细胞、B细胞、树突状细胞、单核/巨噬细胞等，并参与调控肿瘤微环境中肿瘤细胞及免疫细胞的增殖、黏附、生长及分化，最终影响着免疫细胞的抗肿瘤作用。本文将对SLAMF7调控免疫细胞抑制肿瘤细胞功能的研究现状进行综述。
Abstract:The signaling lymphocytes activating molecule factor 7(SLAMF7) is not only expressed on the surface of some malignant tumor cells, but also widely expressed in immune cells, including natural killer cells, CD4+T cells, CD8+T cells, B cells, dendritic cells (DCs) and monocytes/macrophages. It can regulate the biological behavior of tumor cells as well as immune cells and contribute to anti-tumor effects of immune cells in tumor microenvironment. Herein, we review the functional role of SLAMF7 in regulating immune cells to suppress tumor progression.
-
Key words:
- SLAMF7 /
- Immune regulation /
- Multiple myeloma /
- Elotuzumab
-
作者贡献王园园：文献收集整理、文章撰写查勇：文章审校、修改和指导张思宇：收集和资料汇总分析
-
[1] Shi J, Bodo J, Zhao X, et al. SLAMF7 (CD319/CS1) is expressed in plasmablastic lymphoma and is a potential diagnostic marker and therapeutic target[J]. Br J Haematol, 2019, 185(1): 145-147. doi: 10.1111/bjh.15393
[2] Lee JK, Mathew SO, Vaidya SV, et al. CS1 (CRACC, CD319) induces proliferation and autocrine cytokine expression on human B lymphocytes[J]. J Immunol, 2007, 179(7): 4672-4678. doi: 10.4049/jimmunol.179.7.4672
[3] Chen S, Yang M, Du J, et al. The Self-Specific Activation Receptor SLAM Family Is Critical for NK Cell Education[J]. Immunity, 2016, 45(2): 292-304. doi: 10.1016/j.immuni.2016.07.013
[4] Balasa B, Yun R, Belmar NA, et al. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways[J]. Cancer Immunol Immunother, 2015, 64(1): 61-73. http://d.old.wanfangdata.com.cn/NSTLQK/NSTL_QKJJ0233922443/
[5] Chen J, Zhong MC, Guo H, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin[J]. Nature, 2017, 544(7651): 493-497. doi: 10.1038/nature22076
[6] Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu[J]. Blood, 2008, 112(4): 1329-1337. doi: 10.1182/blood-2007-08-107292
[7] Guo H, Cruz-Munoz ME, Wu N, et al. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells[J]. Mol Cell Biol, 2015, 35(1): 41-51. doi: 10.1128/MCB.01107-14
[8] Campbell KS, Cohen AD, Pazina T. Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma[J]. Front Immunol, 2018, 9: 2551. doi: 10.3389/fimmu.2018.02551
[9] Kurdi AT, Glavey SV, Bezman NA, et al. Antibody-Dependent Cellular Phagocytosis by Macrophages is a Novel Mechanism of Action of Elotuzumab[J]. Mol Cancer Ther, 2018, 17(7): 1454-1463. doi: 10.1158/1535-7163.MCT-17-0998
[10] Lee JL, Roh SA, Kim CW, et al. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage Ⅳ colorectal cancer[J]. World J Gastroenterol, 2019, 25(11): 1341-1354. doi: 10.3748/wjg.v25.i11.1341
[11] Barrow AD, Colonna M. Exploiting NK Cell Surveillance Pathways for Cancer Therapy[J]. Cancers (Basel), 2019, 11(1). https://www.ncbi.nlm.nih.gov/pubmed/30626155
[12] Ashour R, Ri M, Aly SS, et al. Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myeloma[J]. Int J Hematol, 2019, 110(1): 69-76. doi: 10.1007/s12185-019-02649-3
[13] Kim JR, Mathew SO, Mathew PA. Blimp-1/PRDM1 regulates the transcription of human CS1 (SLAMF7) gene in NK and B cells[J]. Immunobiology, 2016, 221(1): 31-39. doi: 10.1016/j.imbio.2015.08.005
[14] Malaer JD, Marrufo AM, Mathew PA. 2B4 (CD244, SLAMF4) and CS1 (CD319, SLAMF7) in systemic lupus erythematosus and cancer[J]. Clin Immunol, 2019, 204: 50-56. doi: 10.1016/j.clim.2018.10.009
[15] Aldhamen YA, Seregin SS, Aylsworth CF, et al. Manipulation of EAT-2 expression promotes induction of multiple beneficial regulatory and effector functions of the human innate immune system as a novel immunomodulatory strategy[J]. Int Immunol, 2014, 26(5): 291-303. doi: 10.1093/intimm/dxt061
[16] Pazina T, James AM, MacFarlane AW 4th, et al. The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms[J]. Oncoimmunology, 2017, 6(9): e1339853. doi: 10.1080/2162402X.2017.1339853
[17] Hsi ED, Steinle R, Balasa B, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma[J]. Clin Cancer Res, 2008, 14(9): 2775-2784. doi: 10.1158/1078-0432.CCR-07-4246
[18] Bouchon A, Cella M, Grierson HL, et al. Activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family[J]. J Immunol, 2001, 167(10): 5517-5521. doi: 10.4049/jimmunol.167.10.5517
[19] Pazina T, James AM, Colby KB, et al. Enhanced SLAMF7 Homotypic Interactions by Elotuzumab Improves NK Cell Killing of Multiple Myeloma[J]. Cancer Immunol Res, 2019, 7(10): 1633-1646. doi: 10.1158/2326-6066.CIR-18-0579
[20] Li Y, Cao G, Zheng X, et al. CRACC-CRACC Interaction between Kupffer and NK Cells Contributes to Poly Ⅰ:C/D-GalN Induced Hepatitis[J]. PLoS One, 2013, 8(9): e76681. doi: 10.1371/journal.pone.0076681
[21] De Calisto J, Wang N, Wang G, et al. SAP-Dependent and -Independent Regulation of Innate T Cell Development Involving SLAMF Receptors[J]. Front Immunol, 2014, 5: 186. https://pubmed.ncbi.nlm.nih.gov/24795728/
[22] Bae J, Song W, Smith R, et al. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma[J]. Br J Haematol, 2012, 157(6): 687-701. doi: 10.1111/j.1365-2141.2012.09111.x
[23] Aldhamen YA, Rastall DPW, Chen W, et al. CRACC-targeting Fc-fusion protein induces activation of NK cells and DCs and improves T cell immune responses to antigenic targets[J]. Vaccine, 2016, 34(27): 3109-3118. doi: 10.1016/j.vaccine.2016.04.068
[24] Roma-Rodrigues C, Mendes R, Baptista PV, et al. Targeting Tumor Microenvironment for Cancer Therapy[J]. Int J Mol Sci, 2019, 20(4). pii: E840. doi: 10.3390/ijms20040840
[25] Murata Y, Saito Y, Kotani T, et al. CD47-signal regulatory protein alpha signaling system and its application to cancer immunotherapy[J]. Cancer Sci, 2018, 109(8): 2349-2357. doi: 10.1111/cas.13663
[26] He Y, Bouwstra R, Wiersma VR, et al. Cancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis[J]. Nat Commun, 2019, 10(1): 533. doi: 10.1038/s41467-018-08013-z
[27] Kikuchi J, Hori M, Iha H, et al. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7[J]. Leukemia, 2020, 34(1): 180-195. doi: 10.1038/s41375-019-0525-6
[28] Postelnek J, Neely RJ, Robbins MD, et al. Development and Validation of Electrochemiluminescence Assays to Measure Free and Total sSLAMF7 in Human Serum in the Absence and Presence of Elotuzumab[J]. AAPS J, 2016, 18(4): 989-999. doi: 10.1208/s12248-016-9912-3
[29] Ishibashi M, Soeda S, Sasaki M, et al. Clinical impact of serum soluble SLAMF7 in multiple myeloma[J]. Oncotarget, 2018, 9(78): 34784-34793. doi: 10.18632/oncotarget.26196
[30] Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial[J]. Cancer, 2018, 124(20): 4032-4043. doi: 10.1002/cncr.31680
[31] Gogishvili T, Danhof S, Prommersberger S, et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes[J]. Blood, 2017, 130(26): 2838-2847. doi: 10.1182/blood-2017-04-778423
[32] Kriegsmann K, Kriegsmann M, Cremer M, et al. Cell-based immunotherapy approaches for multiple myeloma[J]. Br J Cancer, 2019, 120(1): 38-44. doi: 10.1038/s41416-018-0346-9
[33] Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma[J]. Leukemia, 2014, 28(4): 917-927. doi: 10.1038/leu.2013.279
[34] Timmers M, Roex G, Wang Y, et al. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen[J]. Front Immunol, 2019, 10: 1613. doi: 10.3389/fimmu.2019.01613
下载:
